相似文献
1
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives.
Int J Mol Sci. 2016 Oct 17;17(10):1725. doi: 10.3390/ijms17101725.
2
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.
Lancet. 2017 Apr 1;389(10076):1357-1366. doi: 10.1016/S0140-6736(16)31320-4. Epub 2016 Nov 24.
3
Disease-modifying treatments for progressive multiple sclerosis.
Mult Scler. 2013 Oct;19(11):1428-36. doi: 10.1177/1352458513502572.
4
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002.
5
Targets of therapy in progressive MS.
Mult Scler. 2017 Oct;23(12):1593-1599. doi: 10.1177/1352458517729455.
6
'Progressive MS - macro views': The need for novel clinical trial paradigms to enable drug development for progressive MS.
Mult Scler. 2017 Oct;23(12):1649-1655. doi: 10.1177/1352458517729457.
7
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.
8
CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
Mult Scler. 2013 Jun;19(7):877-84. doi: 10.1177/1352458512466929. Epub 2012 Nov 24.
9
Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
Mult Scler. 2009 Dec;15(12):1528-31. doi: 10.1177/1352458509351730. Epub 2009 Dec 7.
10
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.
引用本文的文献
1
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS.
Neurol Ther. 2025 May 12. doi: 10.1007/s40120-025-00736-8.
2
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.
J Neurol. 2025 Jan 15;272(2):109. doi: 10.1007/s00415-024-12797-0.
3
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience.
Curr Neuropharmacol. 2024;22(2):339-345. doi: 10.2174/1570159X22666231002142709.
4
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications.
Front Neurol. 2022 Aug 30;13:996342. doi: 10.3389/fneur.2022.996342. eCollection 2022.
5
Brain Structural and Functional Alterations in Multiple Sclerosis-Related Fatigue: A Systematic Review.
Neurol Int. 2022 Jun 8;14(2):506-535. doi: 10.3390/neurolint14020042.
6
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study.
Int J Environ Res Public Health. 2022 May 17;19(10):6069. doi: 10.3390/ijerph19106069.
7
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders.
Int J Mol Sci. 2022 Mar 30;23(7):3829. doi: 10.3390/ijms23073829.
8
Vitamin D and Depressive Symptoms in Adults with Multiple Sclerosis: A Scoping Review.
Int J Environ Res Public Health. 2021 Dec 25;19(1):199. doi: 10.3390/ijerph19010199.
9
Association between multiple sclerosis and dietary patterns based on the traditional concept of food nature: a case-control study in Iran.
BMC Neurol. 2021 Nov 18;21(1):453. doi: 10.1186/s12883-021-02483-3.
10
Personalizing Medicine and Technologies to Address the Experiences and Needs of People with Multiple Sclerosis.
J Pers Med. 2021 Aug 12;11(8):791. doi: 10.3390/jpm11080791.
本文引用的文献
1
Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(4):e256. doi: 10.1212/NXI.0000000000000256. eCollection 2016 Aug.
2
Circulating microRNAs as biomarkers in progressive multiple sclerosis.
Mult Scler. 2017 Mar;23(3):403-412. doi: 10.1177/1352458516651141. Epub 2016 Jul 11.
3
MicroRNAs associated with the pathogenesis of multiple sclerosis.
J Neuroimmunol. 2016 Jun 15;295-296:148-61. doi: 10.1016/j.jneuroim.2016.04.014. Epub 2016 Apr 27.
4
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.
Neurotherapeutics. 2016 Jan;13(1):58-69. doi: 10.1007/s13311-015-0409-z.
5
Stem cell therapy in multiple sclerosis: a future perspective.
Neurodegener Dis Manag. 2015;5(3):167-70. doi: 10.2217/nmt.15.6.
6
The crucial role of mast cells in blood-brain barrier alterations.
Exp Cell Res. 2015 Oct 15;338(1):119-25. doi: 10.1016/j.yexcr.2015.05.013. Epub 2015 May 21.
7
Neuroprotection for acute optic neuritis-Can it work?
Mult Scler Relat Disord. 2013 Oct;2(4):307-11. doi: 10.1016/j.msard.2013.02.001. Epub 2013 Mar 13.
8
High doses of biotin in chronic progressive multiple sclerosis: a pilot study.
Mult Scler Relat Disord. 2015 Mar;4(2):159-69. doi: 10.1016/j.msard.2015.01.005. Epub 2015 Jan 24.
9
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.
Lancet Neurol. 2015 Feb;14(2):208-23. doi: 10.1016/S1474-4422(14)70264-9.
10
Pathological mechanisms in progressive multiple sclerosis.
Lancet Neurol. 2015 Feb;14(2):183-93. doi: 10.1016/S1474-4422(14)70256-X.
Zotero 插件